BioPharma Resources

Drug Trial Radar · NCT02462811

A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)

A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose, Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Pain and Opioid-Induced Nausea and Vomiting (OINV)

Last checked: Nov 19, 2026Latest source record: Nov 3, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 552 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

552

Actual

Start

Sep 2014

Primary completion

Jul 2015

Study completion Aug 2015

Sponsor

Lead sponsor
Joseph HazeltonIndustry
Sponsor type
Industry
First posted
Jun 4, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this study are to compare the occurrence and severity of opioid-induced nausea and vomiting (OINV) associated with CL-108 to Norco®, and to demonstrate the efficacy of CL-108 when compared to placebo for the relief of moderate to severe pain In patients with moderate to severe pain following bunionectomy (osteotomy with fixation of the head of the first metatarsal bone).

Conditions

  • Pain
  • Nausea
  • Vomiting

Interventions

  • CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)Drug

  • PlaceboDrug

  • Norco (hyrdocodone 7,5 mg, acetaminophen 325 mg)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The occurrence of opioid-induced nausea and vomiting (OINV) as assessed by an OINV questionnaire comparing CL-108 to Norco® over 48 hours.Time frame: 48 hours
  2. The relief of moderate to severe pain, assessed by visual analog pain intensity scale, comparing CL-108 to placebo over 48 hours (SPID48).Time frame: 48 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Pennsylvania

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.